|

A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy

RECRUITINGSponsored by M.D. Anderson Cancer Center
Actively Recruiting
SponsorM.D. Anderson Cancer Center
Started2024-09-11
Est. completion2026-03-31
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06647134

Summary

To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria

The criteria are:

* Patients aged 18 years and above
* English (conversational level) speaking, with the ability to give informed consent
* Patients with a rheumatologist clinician diagnosis of inflammatory arthritis irAE or PMR irAE following ICI therapy

Exclusion Criteria

* Acutely life-threatening or worsening cancer
* Hearing impairment functionally limiting participation in verbal interview

Conditions3

ArthritisImmune Checkpoint InhibitorsPolymyalgia Rheumatica

Locations1 site

MD Anderson Cancer Center
Houston, Texas, 77030
Y. Jeff Li, MD713-409-1565yli61@mdanderson.org

Browse More Trials

Arthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.